Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B.Y. Ma,Wan-Teck Lim,Boon Cher Goh,Edwin P. Hui,Kwok Wai Lo,Adam Pettinger,Nathan R. Foster,Jonathan W. Riess,Mark Agulnik,Alex Y. Chang,Akhil Chopra,Julie A. Kish,Christine H. Chung,Douglas Adkins,Kevin J. Cullen,Barbara J. Gitlitz,D. Lim,Ka Fai To,K.C. Allen Chan,Y.M. Dennis Lo,Ann D. King,Charles Erlichman,Jun Yin,Brian A. Costello,Anthony T.C. Chan +24 more
Reads0
Chats0
TLDR
Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations and the biomarker results were hypothesis generating and validation in larger cohorts is needed.Abstract:
PurposeThis multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated in an exploratory analysis.Patients and MethodsPatients with multiply pretreated recurrent or metastatic NPC were treated with nivolumab until disease progression. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity. The expression of programmed death-ligand 1 (PD-L1) and human leukocyte antigens A and B in archived tumors and plasma clearance of Epstein-Barr virus DNA were correlated with ORR and survival.ResultsA total of 44 patients were evaluated and the overall ORR was 20.5% (complete response, n = 1; partial response, n = 8). Nine patients received nivolumab for > 12 months (20%). The 1-year overall survival rate was 59% (95% CI, 44.3% to 78.5%) and 1-year progression-free survival (PFS) rate was 19.3% (95% CI, 10.1% to 37.2%). There was no statistical correlation between ORR an...read more
Citations
More filters
Journal ArticleDOI
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang,Shouhao Zhou,Shouhao Zhou,Fang Yang,Xinyue Qi,Xin Wang,Xiaoxiang Guan,Xiaoxiang Guan,Chan Shen,Narjust Duma,Jesus Vera Aguilera,Ashish V. Chintakuntlawar,Katharine A. Price,Julian R. Molina,Lance C. Pagliaro,Thorvardur R. Halfdanarson,Axel Grothey,Axel Grothey,Svetomir N. Markovic,Grzegorz S. Nowakowski,Stephen M. Ansell,Michael L. Wang +21 more
TL;DR: Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment- related adverse events in clinical trials provides an important guide for clinicians.
Journal ArticleDOI
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E.W. Cohen,R. Bryan Bell,Carlo Bifulco,Barbara Burtness,Maura L. Gillison,Kevin J. Harrington,Quynh-Thu Le,Nancy Y. Lee,Rom Leidner,Rebecca L. Lewis,Lisa Licitra,Hisham Mehanna,Loren K. Mell,Adam Raben,Andrew G. Sikora,Ravindra Uppaluri,Fernanda Whitworth,Dan P. Zandberg,Robert L. Ferris +18 more
TL;DR: An expert committee formed by the Society for Immunotherapy of Cancer formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing serve as a foundation to assist clinicians’ understanding of the role of immunotherAPies.
Journal ArticleDOI
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong,Lizhu Lin,Xiaohui He,Jianping Xiong,Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen,Ningning Zhou,Yuanyuan Zhao,Xue Hou,Qing Yang,Li Zhang +16 more
TL;DR: This work presents safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line Therapy in this patient population.
Journal ArticleDOI
The Global Landscape of EBV-Associated Tumors.
TL;DR: The main characteristics of these tumors, their distinct epidemiologies, histological features and degrees of EBV association are described, then how their different patterns ofEBV latency may reflect the alternative latency programmes through which the virus first colonizes and then persists in immunocompetent host is considered.
Journal ArticleDOI
Management of locally recurrent nasopharyngeal carcinoma.
Anne W.M. Lee,Wai Tong Ng,Jimmy Yu-Wai Chan,June Corry,Antti Mäkitie,William M. Mendenhall,Alessandra Rinaldo,Juan P. Rodrigo,Nabil F. Saba,Primož Strojan,Carlos Suárez,Jan B. Vermorken,Sue S. Yom,Alfio Ferlito +13 more
TL;DR: The different salvage treatment options and associated prognostic factors for each of them are reviewed and a treatment algorithm based on the latest available evidence is proposed to discuss the future directions of treatment for locally recurrent NPC.
References
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
TL;DR: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat,Stéphane Champiat,Laurent Dercle,Samy Ammari,Christophe Massard,Antoine Hollebecque,Sophie Postel-Vinay,Sophie Postel-Vinay,Nathalie Chaput,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle,Jean-Charles Soria,Jean-Charles Soria,Charles Ferté,Charles Ferté +15 more
TL;DR: A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
Related Papers (5)
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Li Zhang,Yan Huang,Shaodong Hong,Yunpeng Yang,Gengsheng Yu,Jun Jia,Peijian Peng,Xuan Wu,Qing Lin,Xuping Xi,Jiewen Peng,Mingjun Xu,Dongping Chen,Xiaojun Lu,Rensheng Wang,Xiaolong Cao,Xiaozhong Chen,Zhixiong Lin,Jianping Xiong,Qin Lin,Conghua Xie,Zhihua Li,Jianji Pan,Jingao Li,Shixiu Wu,Yingni Lian,Quanlie Yang,Chong Zhao +27 more
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Yuan Zhang,Lei Chen,Guoqing Hu,Ning Zhang,Xiao-Dong Zhu,Kunyu Yang,Feng Jin,Mei Shi,Yu Pei Chen,Weihan Hu,Zhi-Bin Cheng,Si-Yang Wang,Ye Tian,Xicheng Wang,Yan Sun,Jin-Gao Li,Wen-Fei Li,Yu-Hong Li,Ling-Long Tang,Yan Ping Mao,Guan-Qun Zhou,Rui Sun,Xu Liu,Rui Guo,Guo-Xian Long,Shao-Qiang Liang,Ling Li,Jing Huang,Jin-Hua Long,Jian Zang,Qiao-Dan Liu,Li Zou,Qiong-Fei Su,Bao-Min Zheng,Yun Xiao,Ying Guo,Fei Han,Hao-Yuan Mo,Jia-Wei Lv,Xiao-Jing Du,Cheng Xu,Na Liu,Ying-Qin Li,Melvin L.K. Chua,Fang-Yun Xie,Ying Sun,Jun Ma +46 more
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more